PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)
This article was originally published in PharmAsia News
Executive Summary
Lee Babiss left Roche, one of the world's largest pharmaceutical companies, for a contract research organization position in part because his days as president of drug research were filled less with driving research projects forward and more with containing his group's costs, a reflection of the current state of R&D productivity at major pharmaceutical firms.
You may also be interested in...
Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech In $1.6 Billion Transaction
Deal hinges on approval by Beijing's antitrust czars.
Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech In $1.6 Billion Transaction
Deal hinges on approval by Beijing's antitrust czars.
Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech If $1.6 Billion Transaction Is Approved By Beijing's Antitrust Czars
BEIJING - With the globe's top pharmaceutical players outsourcing ever-expanding chunks of early-stage research to China, the Massachusetts-based Charles River Laboratories has launched a move to merge with China's leading contract research organization, WuXi PharmaTech, in a $1.6 billion transaction